Keros Therapeutics, Inc. Common Stock (NASDAQ: KROS) last traded at $11.21, down 3.45% on the session. The quote above updates while this page is open; the figures below are drawn from Keros Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Keros Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker KROS. Its market capitalisation is $222.26 million.
Valuation measures for Keros Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $222.26M |
|---|---|
| Enterprise value | -$10.06M |
| Price / sales | 14.80 |
| Price / book | 0.85 |
| Beta | 1.10 |
Trailing-twelve-month figures tagged in Keros Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $15.01M |
|---|---|
| Net income (TTM) | -$83.16M |
| EPS (TTM) | -$3.22 |
| Operating margin | -675.82% |
| Return on equity | -31.70% |
| Cash | $257.61M |
Range and volume for KROS over the past 52 weeks.
| 52-week high | $22.55 |
|---|---|
| 52-week low | $9.69 |
| Volume | 71.0K |
| Average volume | 191.7K |
| Previous close | $11.61 |
Invest a chosen dollar amount in Keros Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell KROS.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.